Ipatasertib, however, failed to prove efficacy regarding PFS when combined with paclitaxel versus paclitaxel alone in the treatment of triple-negative as well as hormone-receptor-positive aBC in the phase III IPATunity130 study [60,61]. Here, NR4A1 is linked to aneurysmal bone cyst.